Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow.
<p><strong>BACKGROUND:</strong><em>Plasmodium vivax</em> malaria remains a major public health burden in Myanmar. Resistance to chloroquine (CQ), the first-line treatment for <em>P. vivax</em>, has been reported in the country and has potential to undermine...
| Egile Nagusiak: | , , , , , , , , , , , |
|---|---|
| Formatua: | Journal article |
| Hizkuntza: | English |
| Argitaratua: |
BioMed Central
2017
|